CPMDOTCPharmaceutical PreparationsFiscal year ends December 31

CANNAPHARMARX, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 18, 2026

$0.00+0.00 (0.00%)

Close on Oct 16, 2026

Earnings

Quarterly results announced on Form 8-K, Item 2.02

Cannapharmarx has not filed an earnings release (Form 8-K, Item 2.02) that we could match to a fiscal quarter.

Announcements Cannapharmarx filed with the SEC

Jan 12, 2026, 7:02 PM ET
EX-99.1 to Form 8-K
Executive or director change · Other events · EX-99.1 to Form 8-K
Jan 12, 2026, 7:02 PM ET
CannaPharmaRX Provides Corporate Update and Outlines Growth Strategy for 2026
Executive or director change · Other events · EX-99.2 to Form 8-K
May 6, 2025, 1:58 PM ET
CannapharmaRx Continues into New European Market with First Shipment Completed to Germany
Other events · EX-99.1 to Form 8-K
Feb 16, 2022, 4:01 PM ET
CALGARY, AB / ACCESSWIRE / February 10,
Regulation FD disclosure · EX-99.6 to Form 8-K

Parsed from the XBRL in Cannapharmarx's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-10 reverse split on Nov 10, 2006
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is CPMD.

Revenue growth24.8% · median 0.5%

Gross margin-88.8% · median 43.2%

Net margin-666.2% · median -51.7%

Advertisement
300 × 250